Table 1 Overall Survival prognostic model in the training set (N = 636; 15 imputations)—Multivariate Cox proportional hazard model.

From: A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries

Prognostic factors

β (95% CI)

HR (95% CI)

P-value

Age ≥ 80 years

0.71 (0.23; 1.19)

2.03 (1.26; 3.28)

0.004

ECOG performance status>1

0.47 (0.26; 0.69)

1.60 (1.29; 1.99)

<0.001

Adverse cytogenetic risk

0.68 (0.44; 0.92)

1.98 (1.56; 2.51)

<0.001

Unknown cytogenetic risk

0.51 (0.21; 0.82)

1.67 (1.24; 2.26)

0.001

WBC > 50 Giga/L

0.35 (0.14; 0.56)

1.42 (1.15; 1.75)

0.001

Secondary AML

0.19 (−0.03 ;0.41)

1.21 (0.97; 1.51)

0.086

NPM1+, FLT3-ITD−

−0.31 (−0.60; −0.03)

0.73 (0.55; 0.97)

0.031

Unknown NPM1 or FLT3-ITD mutation

−0.15 (−0.35; 0.05)

0.86 (0.70; 1.05)

0.137

  1. LP = 0.71 (if age ≥ 80 y) + 0.47 (if PS ≥ 2) + 0.68 (if adverse cytogenetic risk) + 0.51 (if missing cytogenetic risk) + 0.35 (if WBC > 50 G/L) + 0.19 (if secondary AML) −0.31 (if NPM1 mutation and no FLT3-ITD mutation) − 0.15 (if missing NPM1 or FLT3-ITD).
  2. ESS70+ =5# (if age ≥ 80 y) + 3 (if PS ≥ 2) + 4 (if adverse cytogenetic risk) + 3 (if missing cytogenetic risk) + 2 (if WBC > 50 G/L) + 1 (if secondary AML) − 2 (if NPM1 mutations and no FLT3-ITD mutation) − 1 (if missing NPM1 or FLT3-ITD).
  3. #(β-coefficient/abs(lowest β-coefficient)) rounded off to the nearest integer.
  4. CI Confidence Interval, HR Hazard Ratio, WBC White Blood Cell Count, LP Linear Predictor of death risk, PS ECOG Performance Status, ESS European scoring system.
Back to article page